Inhibidores de la ciclooxigenasa-2 en la prevención del cáncer

Koki, 1999, Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy, Exp Opin Invest Drugs, 8, 1623, 10.1517/13543784.8.10.1623 Danemberg, 2001, Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer, Lancet Oncol, 2, 544, 10.1016/S1470-2045(01)00488-0 Thun, 2002, Nonsteroidal anti-inflamatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J Natl Cancer Inst, 94, 252, 10.1093/jnci/94.4.252 Vainio, 2001, Is COX-2 inhibition a panacea for cancer prevention?, Int J Cancer, 94, 613, 10.1002/ijc.1518 Picó Navarro, 2002, Quimioprevención del cáncer de mama, Rev Cancer (Madrid), 16, 138 Altisent, 2001, Ética de la actividad preventiva en Atención Primaria, Med Clin (Barc), 117, 740, 10.1016/S0025-7753(01)72243-9 Bennett, 1977, Prostaglandins and breast cancer, Lancet, 2, 624, 10.1016/S0140-6736(77)92496-5 Hansen-Petrik, 2002, Selective inhibition of Δ-6 desaturase impedes intestinal tumorigenesis, Cancer Letters, 175, 157, 10.1016/S0304-3835(01)00715-7 Liu, 2001, Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice, J Biol Chem, 276, 18563, 10.1074/jbc.M010787200 Vadlamudi, 1999, Regulation of cyclooxygenase-2 pathway by HER2 receptor, Oncogene, 18, 305, 10.1038/sj.onc.1202307 Subbaramaiah, 2002, Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3, J Biol Chem, 277, 18649, 10.1074/jbc.M111415200 Howe, 2002, Celecoxib, a selective Cyclooxygenase 2 inhibitor, protects against human epidermal factor receptor 2 (HER-2)/neu-induced breast cancer, Cancer Res, 62, 5405 Hao, 1999, Early expression of cyclo-oxigenase-2 during sporadic colorectal carcinogenesis, J Pathol, 187, 295, 10.1002/(SICI)1096-9896(199902)187:3<295::AID-PATH254>3.0.CO;2-Y Kucherlapati, 2001, Mouse models for human familial adenomatous polyposis, Semmin Cancer Biol, 11, 219, 10.1006/scbi.2001.0368 Sonoshita, 2002, Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps, Cancer Res, 62, 6846 Sunayama, 2002, The role of Cyclooxygenase-2 in two different morphological stages of intestinal polyps in APC D474 knockout mice, Carcinogenesis, 23, 1351, 10.1093/carcin/23.8.1351 Müller-Decker, 2002, Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis, Proc Natl Acad Sci, 99, 12483, 10.1073/pnas.192323799 Fisher, 1999, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis, Mol Carcinog, 25, 231, 10.1002/(SICI)1098-2744(199908)25:4<231::AID-MC1>3.0.CO;2-F Reddy, 2000, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res, 60, 293 Brown, 2001, Non-steroidal anti-inflamatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a model by inducing apoptosis and inhibiting cell proliferation, Gut, 48, 660, 10.1136/gut.48.5.660 Yoshimatsu, 2001, Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer, Clin Cancer Res, 7, 3971 Zweifel, 2002, Direct evidence for a role of cyclooxygenase 2-derived Prostaglandin E2 in human head and neck Xenograft tumors, Cancer Res, 62, 6706 Hansen-Petrik, 2002, Prostaglandin E2 protects intestinal tumors from nonosteroidal anti-inflamatory drug-induced regression in Apc Min/+ mice, Cancer Res, 62, 403 Bhattacharya, 1998, Nuclear localization of prostaglandin E2 receptors, Proc Natl Acad Sci, 95, 15792, 10.1073/pnas.95.26.15792 Chan, 1998, Mechanisms underlying nonsteroidal antiinflamatory drug-mediated apoptosis, Proc Natl Acad Sci, 95, 681, 10.1073/pnas.95.2.681 Kim, 2004, Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-(B as a possible target, J Cancer Res Clin Oncol, 130, 551, 10.1007/s00432-004-0567-6 Gisbert, 2003, Ciclooxigenasa 2 (COX-2), Helicobacter pylori y cáncer gástrico, Med Clin (Barc), 120, 189, 10.1157/13043139 Correa, 2000, Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements an anti-Helicobacter pylori therapy, J Natl Cancer Inst, 92, 1881, 10.1093/jnci/92.23.1881 El-Omar, 2000, Interleukin-1 polymorphisms associated with increased risk of gastric cancer, Nature, 404, 398, 10.1038/35006081 Schäfer, 2003, Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp-1 and Sp3-dependent activation of two proximal GC-rich promoter elements, J Biol Chem, 278, 8190, 10.1074/jbc.M211999200 Hussain, 2003, Radical causes of cancer, Nature Rev Cancer, 3, 276, 10.1038/nrc1046 Wang, 1998, Chemokines and their role in tumor growth and metastasis, J Immunol Meth, 220, 1, 10.1016/S0022-1759(98)00128-8 Coussens, 2002, Inflamation and cancer, Nature, 420, 860, 10.1038/nature01322 Dvorak, 1986, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, N Engl J Med, 315, 1650, 10.1056/NEJM198612253152606 Tanabe, 2002, Cyclooxygenase isozymes and their gene structures and expression, Prostaglan & other Lipid Mediators, 68-9, 95, 10.1016/S0090-6980(02)00024-2 Jang, 2003, Regulation of expression and potential carcinogenic role of cyclooxygenase-2, 171 Kanekura, 2000, Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells, Cancer Letters, 161, 177, 10.1016/S0304-3835(00)00604-2 Fujita, 2001, Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2, Clin Cancer Res, 7, 3349 Chen, 2004, Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck, Clin Cancer Res, 10, 5930, 10.1158/1078-0432.CCR-03-0677 Llor, 2003, The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes, Clin Nutrition, 22, 71, 10.1054/clnu.2002.0627 Cao, 2002, Many actions of cyclooxygenase-2 in cellular dynamics and in cancer, J Cell Physiol, 190, 279, 10.1002/jcp.10068 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Hahn, 2002, Rules for making human tumor cells, N Eng J Med, 347, 1593, 10.1056/NEJMra021902 Mohammed, 2002, Effects of the cyclooxygenase inhibitor, Piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer, Cancer Res, 62, 356 Hida, 2002, Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents, Clin Cancer Res, 8, 2443 Yao, 2003, Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice, Cancer Res, 63, 586 Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, 60, 1306 Martin, 2002, Nonsteroidal anti-inflamatory drugs, apoptosis, and colorectal adenomas, Gastroenterol, 123, 1770, 10.1053/gast.2002.37053 Hsu, 2000, The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2, J Biol Chem, 275, 11397, 10.1074/jbc.275.15.11397 Johnson, 2001, Apoptosis signaling pathways mediated by Cyclooxygenase-2 inhibitors in prostate cancer cells, Advan Enzyme Regul, 41, 221, 10.1016/S0065-2571(00)00015-7 Patti, 2002, Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib, Cancer Letters, 180, 13, 10.1016/S0304-3835(02)00003-4 Waskewitch, 2002, Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines, Cancer Res, 62, 2029 Tsujii, 1995, Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoside synthase 2, Cell, 83, 493, 10.1016/0092-8674(95)90127-2 Kundu, 2002, Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer, Cancer Res, 62, 2343 Connolly, 2002, Cyclo-oxygenase inhibition reduces tumor growth and metastasis in an orthotopic model of breast cancer, Br J Cancer, 87, 231, 10.1038/sj.bjc.6600462 Kakiuchi, 2002, Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis, Cancer Res, 62, 1567 Jones, 1999, Inhibition of angiogenesis by nonsteroidal anti-inflamatory drugs: insight into mechanisms and implications for cancer growth an ulcer healing, Nature Med, 5, 1418, 10.1038/70995 Habib, 1993, Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2, J Biol Chem, 268, 23448, 10.1016/S0021-9258(19)49483-0 Matsumoto, 2002, Cyclooxygenase-2 differentially directs uterine angiogenesis during implantation in mice, J Biol Chem, 277, 29260, 10.1074/jbc.M203996200 Tsujii, 1998, Cyclooxygenase regulates angiogenesis induced by colon cancer cells, Cell, 93, 705, 10.1016/S0092-8674(00)81433-6 Leahy, 2000, Role of cyclooxygenases in angiogenesis, Current Med Chem, 7, 1163, 10.2174/0929867003374336 Amano, 2003, Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth, J Exp Med, 197, 221, 10.1084/jem.20021408 Williams, 2000, Host cyclooxygenase-2 modulates carcinoma growth, J Clin Invest, 105, 1589, 10.1172/JCI9621 Leahy, 2002, Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo, Cancer Res, 62, 625 Majima, 2000, Ciclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants, Br J Pharmacol, 130, 641, 10.1038/sj.bjp.0703327 Konerding, 2001, 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon, Br J Cancer, 84, 1354, 10.1054/bjoc.2001.1809 Tamura, 2002, Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells, J Clin Endoc Metab, 87, 3504, 10.1210/jc.87.7.3504 Williams, 2000, Celecoxib prevents tumor growth in Vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models, Cancer Res, 60, 6045 Hayashi, 2000, Interferon-g and interleukin 4 inhibit interleukin 1b-induced delayed prostaglandin E2 generation throughout suppression of cyclooxigenase-2 expression in human fibroblasts, Cytokine, 12, 603, 10.1006/cyto.1999.0622 Barbera-Guillén, 2002, Vascular endothelial growth factor secretion by tumor-infiltrating macrofagues essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process, Cancer Res, 62, 7042 Barbera-Guillén, 1999, Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by antitumor antibodies, Neoplasia, 1, 453, 10.1038/sj.neo.7900054 Chen, 2003, Upregulation of tumor interleukin-8 expression by infiltrating macrophagages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer, Clin Can Res, 9, 729 Davies, 2002, Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer Chemoprevention, Ann Oncol, 13, 669, 10.1093/annonc/mdf125 Ogawa, 2000, An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumor-associated angiogenesis, Cytokine, 12, 309, 10.1006/cyto.1999.0562 Ueno, 2000, Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer, Clin Cancer Res, 6, 3282 Iñiguez, 1999, Induction of cyclooxygense-2 on activated T lymphocytes: regulation of T Cell activation by cyclooxygenase-2 inhibitors, J Immunol, 163, 111, 10.4049/jimmunol.163.1.111 Stolina, 2000, Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of OL-10 and IL-12 synthesis, J Immunol, 164, 361, 10.4049/jimmunol.164.1.361 Harizi, 2002, Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, wich down-regulates dendritic cell functions, J Immunol, 168, 2255, 10.4049/jimmunol.168.5.2255 Sharma, 2003, Tumor cyclooxygenase 2-dependent suppression of dendritic cell function, Clin Cancer Res, 9, 961 Baron, 2003, A randomized trial of aspirin to prevent colorectal adenomas, N Engl J Med, 348, 891, 10.1056/NEJMoa021735 Sandler, 2003, A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer, N Engl J Med, 348, 883, 10.1056/NEJMoa021633 Giardello, 1993, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis, N Engl J Med, 328, 1313, 10.1056/NEJM199305063281805 Steinbach, 2000, The effect of celecoxib, a cycloxygenase-2 inhibitor, in familial adenomatous polyposis, N Engl J Med, 342, 1946, 10.1056/NEJM200006293422603 Phillips, 2002, A randomized, double blind, placebo controlled study of Celecoxib, a selective cycloxigenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis, Gut, 50, 857, 10.1136/gut.50.6.857 Khuder, 2001, Breast cancer and NSAID use: a meta-analysis, Br J Cancer, 84, 1188, 10.1054/bjoc.2000.1709 Muscat, 2003, Risk of lung carcinoma among users of nonsteroidal antiinflamatory drugs, Cancer, 97, 1732, 10.1002/cncr.11242 Castelao, 2000, Non-steroidal anti-inflamatory drugs and bladder cancer prevention, Br J Cancer, 82, 1364, 10.1054/bjoc.1999.1106 Bosseti, 2003, Aspirin use and cancer of the upper aerodigestive tract, Br J Cancer, 88, 672, 10.1038/sj.bjc.6600820 Anderson, 2002, Association between nonsteroidal anti-inflamatory drug use and the incidence of pancreatic cancer, J Natl Cancer Inst, 94, 1168, 10.1093/jnci/94.15.1168 Terry, 2004, Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk, JAMA, 291, 2433, 10.1001/jama.291.20.2433 García-Rodríguez, 2004, Risk of breast cancer among users of aspirin and other anti-inflammatory drugs, Brit J Cancer, 91, 525, 10.1038/sj.bjc.6602003 García-Rodríguez, 2004, Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer, Cancer Epidemiol Biomarkers & Prev, 13, 649, 10.1158/1055-9965.649.13.4 Altorki, 2003, Celecoxib, a selective cyclo-oxigenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer, J Clin Oncol, 21, 2645, 10.1200/JCO.2003.07.127 Soslow, 2000, COX-2 is expressed in human pulmonary, colonic, and mammary tumors, Cancer, 89, 2637, 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B Chang, 2004, Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma, Clin Cancer Res, 10, 1678, 10.1158/1078-0432.CCR-03-0354 Ristimäki, 2002, Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer, Cancer Res, 62, 632 Hayden, 2002, Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US. Preventive Services Task Force, Ann Intern Med, 136, 161, 10.7326/0003-4819-136-2-200201150-00016 Leese, 2000, Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial, J Clin Pharmacol, 40, 124, 10.1177/00912700022008766 Lanas, 2000, Impacto económico de los efectos secundarios gastrointestinales asociados a antiinflamatorios no esteroideos en el Servicio Nacional de Salud, Med Clin (Barc), 114, 46 Bombardier, 2000, Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid artritis, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103 Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonesteroidal anti-inflamatorydrugs for osteoarthritis and reumathoid arthritis: the CLASS study: a randomized study. Celecoxib Long-term Arthritis Safety Study, JAMA, 284, 1247, 10.1001/jama.284.10.1247 Deeks, 2002, Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthitis: systematic review of randomised controlled trials, Br Med J, 325, 619, 10.1136/bmj.325.7365.619 Masferrer, 2000, Anti-inflamatories for cardiovascular disease, Proc Natl Acad Sci USA, 97, 12400, 10.1073/pnas.240459597 Mamdani, 2004, Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study, Lancet, 363, 1751, 10.1016/S0140-6736(04)16299-5 Solomon, 2004, Relationship between selective cyclooxygenase inhibitors and acute myocardial infarction in older adults, Circulation, 109, 2068, 10.1161/01.CIR.0000127578.21885.3E Miller, 2003, Cyclooxigenase-2 inhibition for the treatment of cervical intraepithelial neoplasia [abstract 381], Proceed Am Soc Clin Oncol, 22, 95 Ricchi, 2003, Nonsteroidal anti-inflamatory drugs in colorectal cancer: from prevention to therapy, Br J Cancer, 88, 803, 10.1038/sj.bjc.6600829 Winerhalter, 2004, Chemoprevention of lung cancer-from biology to clinical reality, Ann Oncol, 15, 185, 10.1093/annonc/mdh051 Komaki, 2004, Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small lung cancer, Sem Oncol, 47, 10.1053/j.seminoncol.2003.12.014 Klein, 2004, Update on chemoprevention of prostate cancer, Curr Opin Urol, 14, 143, 10.1097/00042307-200405000-00002 Simone, 2004, Cyclooxygenase-2 is essential for HER/neu to suppress N-(hydroxyphenyl) retinamide apoptotic effects in breast cancer cells, Cancer Res, 64, 1224, 10.1158/0008-5472.CAN-03-2188 Wang, 2004, Cyclooxygenase-2: a potential target in breast cancer, Semin Oncol, 1, 64, 10.1053/j.seminoncol.2004.01.008 Benoit, 2004, Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2, Oncogene, 23, 1631, 10.1038/sj.onc.1207295 Gasparini, 2003, Inhibitors of cyclooxygenase 2: a new class of anticancer agents?, Lancet Oncol, 4, 605, 10.1016/S1470-2045(03)01220-8 Grau, 2004, Expression of cyclooxygenase-2 mRNA (COX2-mRNA) in peripheral blood of head and neck cancer patients and healthy controls [abstract], Proc ASCO, 23, 2061 Pruthi, 2004, A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy, BJU Int, 3, 275, 10.1111/j.1464-410X.2004.04601.x Choi, 2003, Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rationale advance?, J Natl Cancer Inst, 95, 1440, 10.1093/jnci/djg058 Bresalier, 2005, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 352, 1071, 10.1056/NEJMoa050405 Nussmeier, 2005, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N Engl J Med, 352, 1081, 10.1056/NEJMoa050330 Psaty, 2005, COX-2 inhibitors-lessons in drug safety, N Engl J Med, 352, 1133, 10.1056/NEJMe058042 Okie, 2005, Raising the safety bar - The FDA's Coxib Meeting, N Engl J Med, 352, 1283, 10.1056/NEJMp058055